Demed Formulation Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.00 M
- Revenue Growth 30.64%
- Profit Growth -20.72%
- Ebitda -139.60%
- Net Worth 20.36%
- Total Assets 40.22%
About Demed Formulation
Demed Formulation Private Limited (DFPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 November 2017 (Seven years and two months 27 days old ). Its registered office is in Kamrup, Assam, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹6.00 M.
Rejuwana Akhter and Mursida Alam serve as directors at the Company.
Company Details
- Location
Kamrup, Assam, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U51909AS2017PTC018209
- Company No.
018209
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Nov 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Who are the key members and board of directors at Demed Formulation?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rejuwana Akhter  | Director | 02-Nov-2017 | Current |
| Mursida Alam | Director | 02-Nov-2017 | Current |
Financial Performance of Demed Formulation.
Demed Formulation Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 30.64% increase. The company also saw a substantial fall in profitability, with a 20.72% decrease in profit. The company's net worth Soared by an impressive increase of 20.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Demed Formulation?
Unlock access to Demed Formulation's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Agrowin Crop Science Private LimitedMursida Alam is a mutual person
Charges (Loans)
₹6.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.60 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Dec 2022 | Others | ₹6.00 M | Open |
How Many Employees Work at Demed Formulation?
Unlock and access historical data on people associated with Demed Formulation, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Demed Formulation, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Demed Formulation's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.